News

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. On Wednesday, the Stop TB Partnership launched a new global plan to end tuberculosis (TB) by 2030. The plan requires a total of $250 billion in funding, $40.2 billion of which would go toward accelerating the research and development of new TB diagnostics, medicines, and vaccines—including a specific goal of developing a new TB vaccine by 2025. There is currently only one licensed TB vaccine, which was approved more than 100 years ago and has limited benefit in adult populations. Several promising candidates are in clinical trials, including four in advanced stages of development, making it possible to have a new TB vaccine by 2025—if sufficient funding and political will is present to push things forward.A new, “all-in-one” vaccine showed early promise in protecting against a variety of coronaviruses, including COVID-19, SARS, and MERS, according to preclinical study results published last week. The mosaic-8 vaccine was able to train immune systems to recognize eight viruses at once in animal studies, demonstrating proof of concept for its ability to block a range of betacoronaviruses—the subgroup containing the virus that causes COVID-19. The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged $30 million to begin clinical trials of the experimental vaccine in humans. The phase 1 trial will take place at Oxford University, which collaborated with the California Institute of Technology to develop the vaccine, and will likely take at least a year.Advances in science, in conjunction with rising investment in research, have led to the development of promising new treatment candidates for several neglected tropical diseases (NTDs) in recent years—though little progress has been made on the NTD subset of parasitic worm diseases. In a new study published last week, researchers outline these NTD research trends, noting that despite a long-standing lack of innovation in drugs for neglected diseases, partnerships between public, private, and nonprofit entities have enabled major progress in developing treatments for several target NTDs like leishmaniasis, Chagas disease, and sleeping sickness. This same progress has not been seen, however, among parasitic worm diseases like schistosomiasis, as research is often left at early stages. Bolstered drug discovery efforts focused on these diseases are needed in order to combat their high global prevalence, the researchers conclude.

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. The World Bank on Thursday approved the creation of a prevention, preparedness, and response financial intermediary fund, or FIF, intended to strengthen national, regional, and global capacities to prevent and prepare for future pandemics. The FIF will pool dedicated resources for pandemic preparedness and response, starting with initial pledges of $1.1 billion—though this represents only around 10 percent of the $10.5 billion the fund will need annually, according to the World Bank and World Health Organization (WHO). WHO will provide technical leadership for the FIF in close collaboration with the World Bank; the scope and structure of its operations and board, however, have not yet been determined. The FIF will also incentivize increased investments from countries, enhance partner coordination, and serve as a platform for advocacy.The US Food and Drug Administration is advising vaccine makes to reformulate their COVID-19 shots to target the BA.4 and BA.5 omicron subvariants, which now account for the majority of US infections and have been growing in prevalence globally, alongside the original strain of the virus. The updated recommendation, announced last week following a vote by a panel of outside experts, is meant to leave enough time for vaccine makers to adapt their formulas and manufacture updated shots to provide broader protection against the virus amid potential fall and winter booster campaigns. The newer forms of the shots will only be offered as boosters, while the primary series of shots will continue to use the original vaccines given their maintained effectiveness against severe outcomes of the virus.The National Institutes of Health has begun testing a universal influenza vaccine that could provide long-lasting protection against a wide range of seasonal flu viruses as well as those with pandemic potential. The vaccine candidate, BPL-1357, is composed of four strains of non-infectious, chemically inactivated, low-pathogenicity avian flu virus. The phase 1 trial, which follows successful preclinical studies, will evaluate BPL-1357 delivered both intranasally and intramuscularly for safety and ability to induce immune responses among up to 100 volunteers. With this new vaccine candidate, scientists are attempting to induce a comprehensive immune response closely mimicking immunity from natural flu infection, as opposed to focusing on inducing immunity to a single viral antigen.

The COVID-19 pandemic has underscored how vital the research and development (R&D) of medical countermeasures is to prevent and combat global health threats. The record-breaking speed at which vaccines, therapeutics, diagnostics, and other tools were developed proved a triumph of modern science. Yet, the pandemic also exposed clear and persistent gaps in our R&D preparedness ecosystem. Absent a crisis, R&D for health preparedness has historically been on the back burner or excluded from preemptive planning to develop local, regional, and global capacities necessary to effectively combat emerging infectious diseases and other health threats. Funding for advanced R&D of medical countermeasures has remained insufficient. And global health security leaders need to crystallize a vision of how to integrate R&D into a broader global preparedness framework. To build a world better equipped to prevent and respond to health threats, we need a more fit-for-purpose, resilient pandemic R&D ecosystem. To achieve that, we must pursue three key areas of reform, as well as recognize the need for these initiatives to support one another:1. Identifying R&D gaps with a strong evidence baseTo solve a problem, you must first understand the nature of it. When COVID-19 hit, not only were there no clear global mechanisms to coordinate and galvanize research efforts to develop vaccines, drugs, and other tools to fight the disease, but we also clearly lacked an understanding and evidence base for what existing R&D and manufacturing capacities existed at a country and regional level, how they could be leveraged to quickly respond to the crisis, and, most importantly, what the major gaps were. While World Health Organization (WHO) frameworks like the International Health Regulations (IHR) and various assessment tools and scorecards existed to help nations assess their health preparedness, none of them sought to comprehensively track R&D readiness metrics. The lack of regionally distributed R&D capabilities deepened inequities in the response, leaving low- and middle-income countries (LMICs) struggling to access the fruits of science, including key supplies and medical countermeasures.As we strive to build a more equity-driven response to future pandemic threats, a stronger evidence base of country-specific data is key to enabling LMICs to highlight and articulate their specific R&D capacity gaps. This will allow for better prioritization of long-term investment in local R&D capacity, ultimately ensuring better access to medical countermeasures. Fortunately, the Global Health Security Agenda (GHSA) exists as a ready-made platform that could support LMICs in both identifying and articulating their R&D capacity gaps and financing needs. GHSA’s new R&D Task Force is in the process of building a metrics tool that countries could utilize to assess and score their pandemic R&D readiness. Through leveraging that evidence base, countries can build a road map for longer-term reforms and a stronger case to guide the allocation and prioritization of future investments in preparedness.2. Developing sustainable financing mechanismsHealth experts from around the world have warned for years that countries, regional bodies, and global institutions must invest more in critical capacities to prevent, detect, and respond to epidemic and pandemic threats. Yet for years, funding for health preparedness, including R&D, has faced a boom-and-bust cycle, with funding surging during a crisis and then subsiding in the aftermath, as funders lose focus on addressing long-term capacity infrastructure. That’s why it is critical, as we consider reforms and new initiatives to strengthen the global health security architecture, that we advance new, more sustainable funding mechanisms to complement national budgets to fill identified preparedness capacity gaps. The proposed Financial Intermediary Fund (FIF) for Pandemic Prevention, Preparedness and Response, which will be housed at the World Bank, is one such exciting prospect. It could address major funding gaps to help LMICs strengthen R&D capabilities. The FIF should be leveraged for investment in coordinated surveillance and rapid development, manufacturing, and equitable delivery of medical countermeasures essential to controlling epidemics and pandemics in every region. While initial resources may be limited, the FIF should seek to bolster all stages of end-to-end product development, ensuring that every country can access the tools and technologies they need to mitigate health threats. The FIF is meant to be a supplementary, long-term fund that will eventually incentivize increased country investments. Integrating a focus on research and innovation within the FIF’s funding priorities from the start is essential to close local and regional R&D capacity gaps. As planning around governance of the FIF advances, GHSA should be given a participatory or coordinating role in this body to help align financing decisions with articulated R&D capacity gaps. 3. Advancing long-term reforms to global governanceAlongside addressing country-specific gaps, reforms must be pursued at a global level to incorporate R&D capacities—including surveillance, laboratory infrastructure, clinical trial, manufacturing, regulatory capabilities, pharmacovigilance, and supply chain management—into international health preparedness and response frameworks. Currently, there is no global framework or process to assess and strengthen national and global R&D readiness within coordinating mechanisms for health security; R&D is not explicitly part of WHO’s IHR or the Joint External Evaluation (JEE).The global community is currently advancing processes to reform the IHR and JEE. As part of that reform, WHO member states should incorporate new indicators into the IHR/JEE designed to specifically assess R&D capabilities, drawing on ideas generated by the GHSA R&D Task Force’s voluntary assessment tool. WHO should also ensure strong linkages between gaps identified and financing directed by the FIF. Additionally, as member states pursue development of a potential new pandemic framework, it is critical that R&D is incorporated as a central pillar to enhance the coordination of research, delineate roles, and ensure clear parameters and standards to facilitate both the development of and access to new tools. The pandemic has shown that systemic gaps continue to stymie the rollout of new technologies to all people, everywhere—perpetuating gross power imbalances between high- and low-income nations and exacerbating entrenched inequalities that have left significant portions of the world’s population without access to lifesaving tools. As we enter year three of the pandemic, it is essential that we do not fall victim to pandemic fatigue, and we seize this moment to enact substantial, meaningful, and coordinated systems change to ensure the world is better equipped to detect, prevent, and respond to pandemic threats. This includes enshrining R&D in global frameworks, securing new sustainable financing for building research capacity, and ensuring that these investments are made based on robust evidence and key metrics that allow countries and global stakeholders to prioritize their preparedness investments. If we fail to make the transformational changes, we will not be ready for the next pandemic.